| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Esperion Therapeutics, Inc. | Chief Financial Officer | Common Stock | 82,751 | $103,025 | $1.24 | 14 Mar 2022 | Direct |
| Esperion Therapeutics, Inc. | Chief Financial Officer | Stock Option (right to buy | 159,000 | 14 Mar 2022 | Direct | ||
| MBX Biosciences, Inc. | Chief Financial Officer | Stock Option (Right to Buy) | 95,000 | 03 Feb 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| MBX | MBX Biosciences, Inc. | 03 Feb 2025 | 1 | $0 | 4 | Chief Financial Officer | 05 Feb 2025, 16:17 |
| MBX | MBX Biosciences, Inc. | 12 Sep 2024 | 1 | $0 | 4 | Chief Financial Officer | 13 Sep 2024, 17:13 |
| MBX | MBX Biosciences, Inc. | 12 Sep 2024 | 0 | $0 | 3 | Chief Financial Officer | 12 Sep 2024, 19:09 |
| ESPR | Esperion Therapeutics, Inc. | 14 Mar 2022 | 1 | $0 | 4 | Chief Financial Officer | 16 Mar 2022, 17:09 |
| ESPR | Esperion Therapeutics, Inc. | 29 Oct 2021 | 1 | $0 | 4 | Chief Financial Officer | 01 Nov 2021, 16:48 |
| ESPR | Esperion Therapeutics, Inc. | 28 Jun 2021 | 2 | $0 | 4 | Chief Financial Officer | 30 Jun 2021, 16:27 |